Posted by Michael Wonder on 08 Nov 2022
NICE final draft guidance adds further treatment option for triple negative breast cancer
8 November 2022 - NICE has today published final draft guidance which recommends pembrolizumab as an option for people with a type of breast cancer called triple-negative breast cancer.
The draft guidance recommends pembrolizumab (Keytruda; MSD) as an option with chemotherapy to try to reduce the size of the tumour before surgery (neo-adjuvant treatment), and on its own as treatment after surgery (adjuvant treatment), for adults with triple-negative early breast cancer at high risk of recurrence or locally advanced breast cancer.
